Ovid Therapeutics Inc. (OVID)
0.34
0.03 (9.78%)
At close: Apr 02, 2025, 3:59 PM
0.36
5.15%
After-hours: Apr 02, 2025, 07:46 PM EDT
Ovid Therapeutics Income Statement
Financials in USD. Fiscal year
is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
| Revenue | 566K | 391.69K | 1.5M | 208.38M | 12.62M | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | n/a | 1.38M | n/a | n/a | 255K | 141.73K | 80.31K | 56.51K | 11.78K | n/a |
| Gross Profit | 566K | 391.69K | 121.14K | 208.38M | 12.62M | -255K | -141.73K | -80.31K | -56.51K | -11.78K | n/a |
| Operating Income | -61.88M | -59.28M | -55.55M | 124.21M | -81.43M | -61.41M | -52.93M | -65.01M | -22.54M | -13.19M | -446.89K |
| Interest Income | 3.9M | 4.9M | n/a | n/a | 395.4K | 948.22K | 952.07K | 201.51K | n/a | 30.28K | n/a |
| Pretax Income | -26.43M | -52.34M | -54.17M | 124.16M | -81.04M | -60.46M | -51.98M | -64.81M | -22.41M | -13.16M | -446.89K |
| Net Income | -26.43M | -52.34M | -51.41M | 122.83M | -80.73M | -59.26M | -51.98M | -64.81M | -22.41M | -13.16M | -446.89K |
| Selling & General & Admin | 25.68M | 31.09M | 32.43M | 37.23M | 30.63M | 19.25M | 19.14M | 15.04M | 12.95M | 6.58M | 341.52K |
| Research & Development | 36.77M | 28.59M | 24.62M | 46.94M | 63.42M | 42.16M | 33.79M | 49.97M | 9.59M | 6.61M | 105.38K |
| Other Expenses | n/a | 1.00 | 1.38M | -45.69K | 395.4K | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 62.45M | 59.67M | 57.05M | 84.17M | 94.05M | 61.41M | 52.93M | 65.01M | 22.54M | 13.19M | 446.89K |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 62.45M | 59.67M | 57.05M | 84.17M | 94.05M | 61.41M | 52.93M | 65.01M | 22.54M | 13.19M | 446.89K |
| Income Tax | n/a | n/a | -2.76M | 1.33M | -306.85K | -1.2M | 951.73K | -80.31K | -950 | n/a | n/a |
| Shares Outstanding (Basic) | 70.91M | 70.58M | 70.42M | 67.48M | 58.45M | 39.22M | 24.63M | 19.34M | 19.6M | 19.6M | 4.75M |
| Shares Outstanding (Diluted) | 70.91M | 70.58M | 70.42M | 68.07M | 58.45M | 39.22M | 24.63M | 19.34M | 19.6M | 19.6M | 4.75M |
| EPS (Basic) | -0.37 | -0.74 | -0.73 | 1.78 | -1.38 | -1.51 | -2.11 | -3.35 | -1.14 | -0.67 | -0.09 |
| EPS (Diluted) | -0.37 | -0.74 | -0.73 | 1.78 | -1.38 | -1.51 | -2.11 | -3.35 | -1.14 | -0.67 | -0.09 |
| EBITDA | -61.88M | -57.69M | -52.79M | 124.4M | -81.12M | -60.21M | -52.79M | -64.73M | -22.48M | -13.18M | -444.58K |
| EBIT | -61.88M | -59.28M | -55.55M | 124.16M | -81.43M | -61.41M | -52.93M | -65.01M | -22.54M | -13.19M | -446.89K |
| Depreciation & Amortization | n/a | 1.6M | 1.38M | 237K | 307K | 255K | 141.73K | 80.31K | 56.51K | 11.78K | 2.31K |